Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
PD-1 inhbitor+SHR0302
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-Small Cell Lung Cancer
1 trial -
PD-1/CTLA-4 Dual Functional Antibody
The First People's Hospital of Lianyungang
Bile Duct Carcinoma
1 trial -
PD-1/PD-L1 inhibitors
BEONE MEDICINES AUS PTY LTD
Borderline Resectable Carcinoma
1 trial -
PD-1inhibitor
Shanghai Chest Hospital
Esophageal Squamous Cell Carcinoma
1 trial -
PD-L1, PD-L2 peptides with Montanide ISA51
IO Biotech
Chronic Lymphocytic Leukemia
1 trial -
PDC-LUNG-101
Lacuna Pharma Pty Ltd
Non-small-cell lung cancer
1 trial -
PEGFILGRASTIM , Rinatabart Sesutecan
Genmab A/S
Locally advanced or metastatic Non-Small Cell Lung Cancer
1 trial -
PEGINTERFERON ALFA-2A for Metastatic Melanoma
Disc Medicine
Metastatic Melanoma
1 trial -
PEGPH20
HALOZYME THERAPEUTICS, INC.
Pancreatic Ductal Adenocarcinoma
1 trial -
PEGPH20
HALOZYME THERAPEUTICS, INC.
Metastatic Pancreatic Cancer
1 trial -
PEGPH20
HALOZYME THERAPEUTICS, INC.
Metastatic Pancreatic Adenocarcinoma
1 trial -
PELICAN-IPC 2015-016
The George Institute
Breast cancer
1 trial -
PEMBROLIZUMAB
Pari Pharma GmbH
Kaposi's sarcoma
1 trial -
PF-03446962
Pfizer
Carcinoma, Hepatocellular
1 trial -
PF-07850327 round
Pfizer Australia Pty Ltd
ADVANCED OR METASTATIC BREAST CANCER
1 trial -
PFL721CI101
Pierre Fabre Medicament
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
PH-ICKPD1-02/21
Philogen S.p.A.
Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy
1 trial -
PH-L19TNFSARC-03/18
Philogen S.p.A.
Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens.
1 trial -
PHERFLOT
The George Institute
HER2-positive, localized esophagogastric adenocarcinoma
1 trial -
PHITAH
Lxo Ireland Designated Activity Company
Basal Cell Carcinoma
1 trial -
PI-88
Biotech Pharmaceutical Co.,
Lung Cancer
1 trial -
PI3K inhibitor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lymphoma, T-Cell
1 trial -
PIK3CA inhibitor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Neoplasm
1 trial -
PIRTOBRUTINIB
Fondazione Telethon ETS
Mantle Cell Lymphoma
1 trial -
PIVEKIMAB SUNIRINE
AbbVie Deutschland GmbH & Co. KG
Acute Myeloid Leukemia and other blood cancers
1 trial -
PLD and Carboplatin
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
PM14, IRINOTECAN
Lacuna Pharma Pty Ltd
Patients with Selected Advanced Solid Tumors
1 trial -
PM14-A-001-17
Lacuna Pharma Pty Ltd
Advanced Solid Tumors
1 trial -
PM8002
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Locally Advanced Non-Small Cell Lung Cancer
1 trial -
POINT
Fondazione Telethon ETS
Adult patients affected by recurrent/metastatic, platinum resistant nasopharyngeal cancer
1 trial -
PRAVASTATIN
The George Institute
Patients with severe and radio-induced breast fibrosis after breast cancer
1 trial -
PRESTO
The George Institute
T1-T2N0 esophageal adenocarcinoma including gastroesophageal junction (GEJ) with indication for radical surgery
1 trial -
PRODIGE 104 A
CERO THERAPEUTICS HOLDINGS, INC.
Resectable borderline pancreatic adenocarcinoma
1 trial -
PRODIGE 107-ENGIC01-COLOSOTO
NORTHWEST BIOTHERAPEUTICS INC
Colorectal Carcinoma
1 trial -
PRODIGE 111
CERO THERAPEUTICS HOLDINGS, INC.
stomach cancer, Esophage, gastro-oesophageal junction adenocarcinoma
1 trial -
PRODIGE 34 - ADAGE
CERO THERAPEUTICS HOLDINGS, INC.
colon cancer
1 trial -
PROICM 2020-04 GAB
The George Institute
local advenced pancreatic adenocarcinoma
1 trial -
PROICM 2021-02 GAB
The George Institute
Metastatic pancreatic adenocarcinoma
1 trial -
PROICM 2021-04 REL
The George Institute
Neuroendocrine tumor
1 trial -
PRT3789
Prelude Therapeutics Inc
Advanced Solid Tumor
2 trials -
PRT3789-02
Prelude Therapeutics Inc
non-small cell lung cancer (NSCLC), Esophageal Cancer, Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
1 trial -
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC
Telix Innovations
Prostate Cancer
1 trial -
PTCL S-IDE
Fondazione Telethon ETS
Relapsed or Refractory Peripheral T-cell Lymphomas
1 trial -
PTG-CARCIK-CD19
Fondazione Telethon ETS
B-Non Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
1 trial -
PTG-CARCIK-CD19
Fondazione Telethon ETS
B cell precursor Acute Lymphoblastic Leukemia
1 trial -
PTT101
Alphapharm Pty Ltd
Central nervous system (CNS) lymphoma; recurrent or refractory primary or isolated secondary
1 trial -
PUMA-ALI-1201
PUMA BIOTECHNOLOGY, INC.
Hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) recurrent or metastatic breast cancer (MBC)
1 trial -
PV-10
PROVECTUS BIOPHARMACEUTICALS, INC.
Melanoma
2 trials
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.